Iltamiocel

Phase 3Cell therapy

CCook MyoSite

Iltamiocel is one of 5 biologic programs targeting Fecal Incontinence. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Fecal IncontinenceActive, not recruiting

Fecal IncontinencePhase 3

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Fecal Incontinence

#DrugCompanyPhaseTrials

Flagyl

DDePuy Orthopaedics

Approved

—2

Neo-Synephrine

EExela Pharma Sciences, LLC.

Iltamiocel

2 4

Botulinum Toxin a

GSK

Phase 1

1 5

Polyethylene Glycols

JJinnah Postgraduate Medical Centre

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Active, not recruiting

Fecal Incontinence

NCT05776277

Clinical

Trials by Indication[1]

Fecal Incontinence2 trials

Autologous Cell Therapy for Treatment of Fecal Incontinence

Completed·CCook MyoSite·Phase 1/2·NCT01600755·53 enrolled

A Two-stage, Randomized, Controlled Trial Comparing the Safety and Efficacy of Iltamiocel With Placebo in the Treatment of Female Participants With Chronic Fecal Incontinence and a History of Obstetric Anal Sphincter Injury (DigniFI)

Active, not recruiting·CCook MyoSite·Phase 3·NCT05776277·200 enrolled

Female1 trial

Autologous Muscle Derived Cells for Female Urinary Sphincter Repair

Completed·CCook MyoSite·Phase 3·NCT01893138·311 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Iltamiocel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Iltamiocel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Iltamiocel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cook MyoSite company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 3[1]
Company: CCook MyoSite

Iltamiocel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Fecal Incontinence2 trials

Female1 trial

References

Drug Info

Quick Facts

Related News